Nuwellis, Inc. To Announce First Quarter 2023 Financial Results on May 9, 2023

Rhea-AI Summary

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, is set to release its Q1 2023 financial results on May 9, 2023. The company will hold a conference call and webcast at 9:00 AM ET to discuss the financial results and provide a general business overview. Investors can access the live webcast on Nuwellis' Investors page or by calling the designated numbers provided for U.S. and international participants.

Nuwellis specializes in treating fluid overload issues with its Aquadex SmartFlow® system, aimed at transforming the lives of affected patients. This system is designed for use in both outpatient and inpatient settings under physician supervision.

Positive

• Upcoming financial results release could provide insight into company performance.
• Potential for growth through commercialization of the Aquadex SmartFlow system.

Negative

• None.

MINNEAPOLIS, April 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company’s financial results and provide a general business overview.

To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10177112. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow^® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn.

About the Aquadex SmartFlow^® System

The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies. 

CONTACTS

INVESTORS:
Vivian Cervantes
Gilmartin Group LLC
ir@nuwellis.com

MEDIA:
Annika Parish
Health+Commerce
annika@healthandcommerce.com

FAQ

What are the financial results release dates for Nuwellis, Inc. (NUWE)?

Nuwellis, Inc. will release its Q1 2023 financial results on May 9, 2023.

How can I access the Nuwellis, Inc. (NUWE) conference call?

The conference call can be accessed by dialing 1-833-816-1404 for U.S. participants or 1-412-317-0497 for international participants.

What is the Aquadex SmartFlow system used for?

The Aquadex SmartFlow system is used for ultrafiltration therapy in patients suffering from fluid overload.

What time is the Nuwellis, Inc. (NUWE) conference call scheduled?

The conference call is scheduled for 9:00 AM ET on May 9, 2023.